39
32
34
36
38
36 Cover Story 09 Dear friends and readers, I hope you would have enjoyed reading our previous issue. Once again, I am delighted to bring to you the July 2019 edition of Microbioz India magazine, supported by the cover story entitled “Biologics vs Biosimilars : Research and Development in Pharma” a review study on comperative study of Biosimilars and Biologics.
Featured article 44 Added to this, the current edition has a special featured guest article entitled “Take a look at Blood with analysis machines ” by maxon precision motor India Pvt Ltd. Includes product description with Blood analysis.Our blood is a fascinating fluid it transports oxygen and nutrients, fends off foreign objects and closes wounds. At least in normal cases some people, however, suffer from coagulation disorders.
Product Launches 14 The edition also covers recent Pharma news articles and product launches collected from worldwide sources to update the readers with the current trends in the industry
Telstar launches BiOptima, a new high-end biosafety cabinet
42
Developed by Telstar, the new high-end Class II biosafety cabinet ensures optimum efficiency and high-level energy savings, as well as presenting a new breakthrough ergonomic design.
New e-books from Freeman Technology offer 41 updated xpert advice on powder tester selection Recent revisions of two popular e-books from Freeman Technology offer clear, expert advice for those looking to invest in powder testing technology. ‘Choosing a Powder Tester’ reviews the technology available and has been updated to include recent innovations such as uniaxial powder testing.
Metrohm Autolab Partners with Arbin Instruments to 39 Create an Integrated Solution for Battery Research Metrohm Autolab and Arbin Instruments have combined their decades of experience to launch a new Electrochemical Impedance Spectroscopy (EIS) solution that can easily be integrated into any battery testing program.
Microbioz India, June 2019
10
ear friends and readers, I hope you would have enjoyed reading our previous issue. Once again, I am delighted to bring to you the July 2019 edition of Microbioz India magazine, supported by the cover story entitled “Biologics vs Biosimilars : Research and Development in Pharma” a review study on comperative study of Biosimilars and Biologics. A biosimilar is exactly what its name implies — it is a biologic that is “similar” to another biologic medicine (known as a reference product) which is already licensed by the U.S. Food and Drug Administration (FDA). Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. In approving biosimilars, the FDA may require that manufacturers conduct a clinical study (or studies) sufficient to establish safety, purity or potency in one or more uses for which the reference product is licensed and the biosimilar seeks licensure. Added to this, the current edition has a special featured guest article entitled “Take a look at Blood with analysis machines ” by maxon precision motor India Pvt Ltd. Includes product description with Blood analysis.Our blood is a fascinating fluid it transports oxygen and nutrients, fends off foreign objects and closes wounds. At least in normal cases some people, however, suffer from coagulation disorders. These cases are unpleasant for the patient and can have severe consequences – or even lead to death. This is why early detection of a blood disorder and the hunt for a cure are so important. This requires a lot of testing. We have the latest market research news and insightful product launches inside, collected from worldwide sources to keep you updated with what is going on in the industry. Dear friends and readers, I hope you find some value in the magazine. Also, I would like to thanks you for being together in this beautiful journey so far. We would love to have your valuable feedback and suggestions as they help us to come up with better content each time. For any further valuable addition, please write to us at editor@microbiozindia.com.
DISCLAIMER: This disclaimer informs readers that the views, thoughts, and opinions expressed in the Articles, Advertisements published in the magaizne belong solely to the author, advertisers and not necessarily to the author’s employer, organization, committee or other group or individual. The published material, adverts, editorials and all other content is published in a Microbioz India magazine cannot guarantee and accepts no liability for any loss or damage of any kind caused by this magazine and errors and for the accuracy of claims made by the advertisers.
Cover Story
Biologics vs Biosimilars Research and Development in Pharma iologics or Biologicals products are medicines made from living organisms through highly complex manufacturing processes and must be handled and administered under carefully monitored conditions. Biologics include a wide variety of products such as gene and cell therapies, therapeutic proteins, monoclonal antibodies, and vaccines. Biologics are used to prevent, treat or cure a variety of diseases including cancer, chronic kidney disease, diabetes, cystic fibrosis, and autoimmune disorders. A biosimilar is exactly what its name implies — it is a biologic that is “similar” to another biologic medicine (known as a reference product) which is already licensed by the U.S. Food and Drug Administration (FDA). Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. In approving biosimilars, the FDA may require that manufacturers conduct a clinical study (or studies) sufficient to establish safety, purity or potency in one or more uses for which the reference product is licensed and the biosimilar seeks licensure.
B
(typically a chemical) as the original product. After Health Canada approval, they can then sell this as a generic version. The original product and the generic copies are considered bioequivalent because the active part of the medicines behave the same way in the body. Biologics: By comparison, Biologics are very large and have complex molecular structures. They are produced by living cells, from highly specialized ingredients using a complex biotechnology process. It is impossible to produce an exact copy without using the exact same
ingredients, the same living cell lines, and identical manufacturing conditions. As with other medicines, once a patent expires for a biologic, it is legal for other manufacturers to reproduce the drug. However, the innovator company doesn’t have to share its patented
Biosimilars – How are these Different? Biosimilars are products that are similar to an already existing brand-name, original biologic (innovator or originator biologic) but, unlike a generic drug, are not identical. To understand why, we need to look at how biologics are different from other medicines. Small Molecule: Most medicines, such as aspirin, are small molecule products, which means they have simple molecular structures. These simple structures make it easy to produce or copy. Once a patent expires, other companies can make copies of small molecule drugs by reproducing the exact same active ingredient
manufacturing processes (which may include the room temperature, the type of cells that produce the biologic, and the food the cells use to grow), and since there is always variability in a live biological system, it is impossible for a biosimilar to be an identical copy. Since biosimilars are not identical, they are not generic versions of the biologic they are copying.
Microbioz India, July 2019
16
Cover Story With small molecule drugs, there are often many generic versions, and they all work the same. For example, whether you buy name brand acetylsalicylic acid (Aspirin) or one of the many generic versions, they perform the same in the body. However, with biologics, there could be many different biosimilars all referencing one innovator medicine and each have a different manufacturing process resulting in a similar molecule to the innovator biologic, but not necessarily as similar to each other. With any biologic product, one batch of a biologic drug may not be exactly the same as the next, but they are required to be within a tight range.
Benefits of Biosimilars The cost of pharmaceuticals, particularly biologics, is an important consideration as experts look at ways to make pharmaceutical care sustainable. Because they are complex and have revolutionized the treatment for many diseases, biologic medicines are costly and consume a large portion of public and private drug spending. In most cases, biosimilars are less costly than the innovator biologic, given that fewer clinical trials are required for biosimilars. Biosimilar manufacturers can extrapolate scientific evidence from one indication to another, which leads to fewer development costs. Biosimilar manufacturers focus on manufacturing processes that result in a similar product as well as studies demonstrating clinical similarity to the innovator biologic. These approaches are less expensive than the clinical trials required for initial drug approval for the innovator biologics. Story source & credit: The story is for information purposes and collected from other sources for more information follow the referral links.
References: https://www.phrma.org/advocacy/researchdevelopment/biologics-biosimilars https://badgut.org/information-centre/a-zdigestive-topics/biosimilars-pamphlet/
Microbioz India, July 2019
18
Business News
Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap Mylan and its EpiPen manufacturing partner Pfizer have had trouble keeping up with demand.
That's not good news as the key back-to-school season nears. Except, perhaps, for Novartis' Sandoz unit and its stepped-up rollout of rival epinephrine injector Symjepi. Amid a long-running EpiPen shortage, Sandoz and its partner Adamis are kicking off a broad retail launch for Symjepi. Sandoz is making adult and pediatric doses of Symjepi available immediately at pharmacies, the drugmaker said Tuesday. Sandoz already launched the med in hospitals and has a sales force detailing it to hospital providers. To bring patients into pharmacies, Sandoz has rolled out a social media program and a new website, Adamis said. It's also hoping to push into schools, which are required in many states to stock epinephrine injectors in case students suffer severe reactions. But that's a tougher task. To make a big dent in that market, Sandoz and Adamis need some state lawmakers to tweak their regulations and change the definition of “auto-injectors.” Symjepi is a syringe, and current rules in some states force them to pay for the pricey EpiPen.
“Along with Sandoz, Adamis is thrilled to bring broad access to this critical medicine for patients,” Adamis CEO Dennis Carlo said in a statement. “We expect that Symjepi will play a role in ending the chronic shortages of epinephrine injection products in the U.S.” EpiPen shortages popped up after an FDA inspection in 2017 found serious issues at the Pfizer plant where the auto-injectors are made. At the time, Pfizer said that Meridian, a subsidiary that manufactures the pens, was suffering "manufacturing constraints," but it was working with Mylan to improve "consistent availability." Amid an ongoing shortage, the FDA has worked with Pfizer and Mylan to extend EpiPen expiration dates. Meanwhile, rival drugmakers have been working to push their alternatives with varying success. And it's not just EpiPen that's running short now. Amneal said Wednesday it expects supply issues at a third-party provider to hit Adrenaclick sales during the critical third quarter when parents and schools stock up for the upcoming school year. Sandoz and Adamis launched Symjepi early this year at $250 for a two-pack, compared with more than $600 for Mylan's EpiPen. Amid a pricing firestorm, Mylan launched a half-priced authorized generic in 2016. Fierce competition in the market after Mylan’s EpiPen pricing firestorm spawned some questionable business practices, according to a recent lawsuit from Adamis. The company said that right after it won FDA approval for Symjepi, rival Kaléo bought up similar domain names and redirected traffic to its own Auvi-Q website. Kaléo didn’t respond to a request for comment from FiercePharma. The story source and Credit: The story is for information purposes for more information, Fiercepharma authored by: by Eric Sagonowsky
Microbioz India, July 2019
20
Business News
Sun Pharma and China Medical System Holdings enter into a License Agreement for Cyclosporine A eye drops in Greater China 1. Relationship gives Sun Pharma access to dry eye market in Greater China 2. Greater China to become a key market in future with more than 100 million1,2 people currently suffering from dry eye disease Mumbai, India June 27, 2019 – Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its
subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries has entered into an exclusive licensing agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for the development and commercialization of Cyclosporine A 0.09% (CsA) eye drops, an innovative formulation, for dry eye disease in Greater China (including Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan). Under terms of the license agreement, CMS will pay Sun Pharma an initial upfront payment,
regulatory and sales milestone payments, and royalties on net sales, the terms of which are confidential. CMS will be responsible for development, regulatory filings and commercialization of the product in China. The initial tenure of the agreement shall be 15 years from the first commercial sale of CsA in Greater China, and may be extended for additional 3 years subject to certain conditions defined in the agreement. “We are pleased to enter into a licensing arrangement with CMS, a leading pharmaceutical company in Greater China. Dry Eye disease represents an area of high unmet medical need, with a significant number of patients having moderate to severe form of this disease. Sun Pharma is committed to growing its global ophthalmology franchise, with cyclosporine as its lead product.” said Kirti Ganorkar, Executive Vice President and Head, Global Business Development, Sun Pharma.
About Cyclosporine A 0.09% (CsA) eye drops Cyclosporine A 0.09% ophthalmic solution (CsA) is a patented, novel, proprietary nanomicellar formulation in a clear, preservative-free, aqueous solution. This nanomicellar technology uses micelles, which are gelatinous aggregates of amphipathic (both hydrophobic and hydrophilic)molecules formed at a welldefined concentration. The small size of the nanomicelles facilitates entry into corneal and conjunctival cells, enabling delivery of high concentrations of CsA. In a multicentered, randomized, double-masked, vehicle-controlled Phase 3 confirmatory study, 744 patients with dry eye were treated either with CsA or its vehicle. After 12 weeks of treatment, as compared to vehicle, CsA showed statistically significant improvement in the primary end point, Schirmer’s score (a measurement of tear production) (p<0.01). Additionally, several key secondary endpoints showed statistically significant improvements compared to vehicle, with some
Microbioz India, July 2019
22
Business News showing improvement as early as 1 month following treatment. Adverse events reported in the trial were mostly mild in nature. In a prior Phase 2b/3 clinical trial with 455 patients, CsA demonstrated increased tear production (p<0.01) and was well tolerated by the study population. Additionally, several key secondary endpoints showed statistically significant improvements compared to vehicle. The most common adverse reaction following the use of cyclosporine ophthalmic solution 0.09% was instillation site pain (22%) and conjunctival hyperemia (6%).Other adverse reactions reported in 1% to 5% of the patients were eye irritation, blepharitis urinary tract infection, headache, and bronchitis. Sun Pharma acquired global rights and intellectual property for Cyclosporine A 0.09% ophthalmic solution through the acquisition of Ocular Technologies, Sarl, a portfolio company of Auven Therapeutics (Auven), an international private equity company. The product was approved by US FDA in August 2018 under the CEQUAâ&#x201E;˘ brand name.
Indications and Usage Cyclosporine A 0.09% ophthalmic solution is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye). Important safety information Warnings and
The most common adverse reactions reported in greater than 5% of patients were pain on instillation of drops (22%) and conjunctival hyperemia (6%). Other adverse reactions reported in 1% to 5% of patients were blepharitis, eye irritation, headache, and urinary tract infection.
About Dry Eye Disease Dry eye is a burdensome, chronic disease affecting millions of patients around the world, with a significant population, greater than 100 million1,2 patients, present in Greater China. Dry eye disease occurs when the quantity and/or quality of tears fails to keep the surface of the eye properly lubricated. The disease causes a scratchy sensation or a feeling that something is in the eye. Other symptoms include stinging or burning, episodes of excess tearing following periods of stress, discharge, pain, and redness in the eye. The risk of developing dry eye increases with advancing age, and is more common in women than in men.
About Sun Pharmaceutical Industries Ltd. (CIN L24230GJ1993PLC019050) Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 7% of annual revenues in R&D. For further information, please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live
precautions
About CMS
Potential for Eye Injury and Contamination:
CMS is a well-established, innovation-driven specialty pharma company with focus on sales and marketing in China. CMS is committed to offering competitive products and services to meet China's unmet medical needs with a strong and professional sales and marketing network as well as a promotion platform covering the whole Chinese market. It is listed on the Hong Kong Stock Exchange (867.HK). For more information, please see https://en.cms.net.cn/CmsNewWebEn/Index.as px
To avoid the potential for eye injury and Contamination, advise patients not to touch the vial tip to the eye or other surfaces. Use with Contact Lenses: Cyclosporine A 0.09% ophthalmic solution should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of Cyclosporine A 0.09% ophthalmic solution.
Adverse Reactions
Microbioz India, July 2019
24
Business News Disclaimer Statements in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied.
References 1. Experts’ consensus about clinical diagnosis and treatment of dry eye, 2013 2. Prevalence, Burden, and Pharmacoeconomics of Dry Eye Disease
Contacts: Investors: Media: Nimish Desai Gaurav Chugh Tel +91 22 4324 4324, Xtn 2778 Tel +91 22 4324 4324, Xtn 5373 Tel Direct +91 22 4324 2778 Tel Direct +91 22 4324 5373 Mobile +91-98203 30182 Mobile +91 98104 71414 E mail nimish.desai@sunpharma.com E mail gaurav.chugh@sunpharma.com
With test, Merck takes temperature-controlled drug delivery by drone from remote idea to remote locations
Drugmakers have speculated about delivering temperature-sensitive vaccines and drugs to remote locations using drones. Now, Merck & Co. is testing the method. Merck initiated the idea, and a collection of players coordinated by humanitarian aid organization Direct Relief have now moved to proof-ofconcept missions. They developed and flew a drone with a temperature-controlled payload over the waters around the Bahamas. "This successful pilot demonstrates the potential of innovative unmanned aerial vehicles technology to aid in delivery of temperature-dependent medicines and vaccines to people who critically need them," Craig Kennedy, Merck's senior vice president of supply chain, said in a statement. Drone maker Volans-i built and operated the allelectric drones, while packaging expert Softbox developed the temperature-controlled payload box. Merck provided supply chain consulting. The unmanned aerial vehicle flew over open water between the islands of the Bahamas and out of sight of the operator. The cold-chain delivery technology on the drone permitted precise temperature control to minus 70 degrees Celsius, a temperature required for storing and transporting some vaccines and drugs. Cloud-based technology from AT&T allowed continuous temperature tracking and real-time data collection and analysis during the flight. Vaccine makers have long been working on how to get heat-sensitive vaccines to remote areas before they spoil. Progress has been made into making some of them so they can be moved at ambient temperatures, but that cannot always be achieved. Merck has a lot of experience with this. Its experimental Ebola vaccine, for example, is currently being used in an Ebola outbreak that started in remote locations in the Democratic Republic of Congo. The Bahamas flight was the fourth pilot effort, and testing will next be taken to Africa and Latin America. The group acknowledged that while the technology is promising, its viability in the real-world will
Microbioz India, July 2019
26
Business News depend on many factors, not the least of which are â&#x20AC;&#x153;evolving regulatory challenges.â&#x20AC;? Still, the partners consider it an important step forward, particularly for the most vulnerable people and parts of the world. "Experience and research consistently show that those most at risk of health crisis in disasters live in communities which are likely to be cut off from essential health care due to disruption of
transportation and communications," said Andrew Schroeder, analytics guru for Direct Relief. "Drone delivery is one of the most promising answers to this problem." The story source and Credit: The story is for information purposes for more information, Fiercepharma authored by: by Eric Palmer
Product Launch
The Complete Validation of Environmental Monitoring introduced by Titan Biotech Ltd n every industry, environment must be mandatorily free of contaminants. Environmental monitoring plays a crucial role to assess any viable and nonviable microbial growth. The process must be run at regular intervals, but it becomes along and tedious task.This is unavoidable specifically for pharmaceutical industries. Any ignorance can risk the efficacy of drugs, vaccines and ultimately patient’s health. TITAN BIOTECH LTD. Has launched a complete solution for the monitoring of all the critical areas of clean rooms, isolators and operating theatres. TITAN BIOTECH LTD., the company has carved a name for itself in biotechnology industry. Majorly for its microbiology products, the company has gained success in over 77 countries around the globe. The newly launched range of products is represented by the brand ‘ABSOLUTE EM’. The brand covers a list of Ready-to-Use Plates, Air Monitoring System and Biological Indicators for the most secured and safest validation processes.
I
“We at Titan are always determined to fulfil all microbiological needs.In 1992, we began with the in- house production of
Biological media bases. Now we are proudly manufactuing and exporting more than 1800 Culture Media.Recently, we have introduced automatic production line of Ready to Use plates.”quoted By Mr. Udit Singla, Vice President. The plates are manufactured with fully- automatic aseptic media pouring systems and prepared in a uni-directional flow of air in a Class 5 clean room environment. Triple-packaged Ready-to-Use Plates are gamma irradiated and carries the advanced colour changing VHP and radiation indicator to verify any risk of contamination.ABSOLUTE EM’s Ready to use plates support the easiest comfort and assured results. The brand believes that the products must always be user-friendly. Taking one step ahead, the details including product name, code, batch no., manufacturing date, expiry date are printed on edge of plate. The users have an ease of reading colonies on colony counter. Another significant point to be noted for Pharmaceutical companies. The culture media is quality assured as per the norms laid down by International Pharmacopeia i.e. USP,EP,BP, JP & IP. For the active and passive air monitoring, ABSOLUTE EM has brought in Air Sampler and 90mm plates. The rodac plates (55mm) are designed for microbiology surface and personnel testing. Variants including Soya Casein Digest Agar and Sabouraud Dextrose Agar are part of the wide list, along with β Lactamase and other neutralisers. ABSOLUTE EM complements the requirements of Pharmaceutical industry with its outspread features. It is a complete solution for user convenience, effective performance and secure validation. Know More: www.tmmedia.in For more information write to: marketing@titanbiotechltd.com
Microbioz India, July 2019
30
Product Launch
New-Generation Benchtop Mass Spectrometer Advances Quantitative Proteomics and Translational Research Thermo Scientific Orbitrap Exploris 480 mass spectrometer designed for high-throughput biopharmaceutical and academic research laboratories A new compact, benchtop mass spectrometer unlocks the power of an advanced differential ion mobility interface option and internal standard-
triggered methods, to deliver high levels of performance in high-throughput laboratory environments. This innovative new technology is designed for advanced protein analysis, quantitative proteomics and small molecule applications for biopharmaceutical and translational research scientists. The new Thermo Scientific Orbitrap Exploris 480 mass spectrometer (MS) combines proven technology, advanced capabilities and intelligencedriven data acquisition strategies for rigorous, highthroughput protein identification, quantitation and structural characterization of biotherapeutics and translational biomarkers. The introduction of the Orbitrap Exploris 480 leads Thermo Fisher’s growing portfolio of new-generation MS solutions. The system provides enhanced quantitative performance across label-free and tandem mass tag (TMT) experiments, as well as access to new
Thermo Scientific SureQuant methods for ultrasensitive targeted protein assays. This combination allows researchers to conduct rapid, multiplexed analysis of proteins within complex biological matrices. With a smaller footprint than previous generations, the new system maximizes laboratory bench space while maintaining high-resolution, mass accuracy and spectral quality. Additionally, the Orbitrap Exploris 480 MS has many new features to extend uptime and improve serviceability for
researchers in high-throughput laboratory environments. Thermo Fisher Scientific showcased its new instrument during the 67th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held June 2–6, in the International Ballroom ABCD at the Omni CNN Center Hotel, Atlanta, Georgia. "With increased appreciation for quantitative proteomics as an essential biopharmaceutical and translational research technique, there is a growing need for a mass spectrometry system that can support large-scale translational studies with no sacrifice in overall system performance," said Ken Miller, vice president, life sciences mass spectrometry marketing, Thermo Fisher Scientific. "The Orbitrap Exploris 480 MS addresses this need, offering extended access to exceptional, high-quality quantitative results in a compact, serviceable platform with specific new methods for comparative and targeted protein analysis." As a new addition to Thermo Fisher’s industryleading MS portfolio, Orbitrap Exploris 480 users will experience the immediate convenience and benefits of a common method programming interface and sources, shared with Thermo Scientific Tribrid and Triple-stage Quadrupole (TSQ) instruments. For example, the Orbitrap Exploris 480 MS takes full advantage of the Thermo Scientific FAIMS Pro interface, which can boost the already-extensive proteome coverage of the instrument by 20 percent. Prof. Jesper V. Olsen, of The Novo Nordisk Foundation Center for Protein Research, said, "The FAIMS Pro interface is a perfect match for the fastscanning and compact Orbitrap Exploris 480 mass spectrometer. In shotgun analyses of proteomes, we can now identify significantly more proteins with very short liquid chromatography gradients. This enables high-throughput screening of hundreds – or even thousands – of samples while maintaining protein depth and quantitative accuracy."
Microbioz India, July 2019
32
Product Launch Users of the Orbitrap Exploris 480 MS will benefit from: Expanded protein coverage through enhancements to instrument design and use of the Thermo Scientific FAIMS Pro interface to enhance precursor ion selectivity. Management of this interface is fully incorporated into control software for easy integration. The ability to analyze a wide range of compounds, from small molecules, to peptides and intact proteins and complexes, enabled by a wide mass range of 40 to 6,000m/z(with the option to increase the range to 8,000m/zby using BioPharma mode). Enhanced quantitative methods and results that improve results for label-free and Thermo Scientific TMT Isobaric Mass Tagging Kits for multiplexed MS2 differential peptide quantitation experiments. Rapid development and deployment of targeted assays for large proteins provided by the new Thermo Scientific SureQuant internal standardtriggered methods for ultra-sensitive targeted protein assays. SureQuant methods are available for the SureQuant AKT/mTOR Pathway Kit and the Biognosys PQ500 kit for the targeted quantitation of 500 plasma proteins. The Orbitrap Exploris 480 mass spectrometer can easily be integrated into a laboratory’s routine workflows with the Thermo Scientific Almanac web-based application, which allows users to view instrument operation and data acquisition in real time and receive notifications on the status of runs. This offers scientists the convenience of improved visibility to the utilization of their laboratory systems, no matter how busy they are or where they are. The source / credit of story is: Thermo Fisher Scientific
Controlled Rate Freezing of Biological Samples SP Scientific introduces the new BioCool V40 - a robust and reliable mechanically refrigerated 1.5litre system designed for controlled rate freezing of biological materials including blood, embryos and tissue samples.
The BioCool V40 is the only controlled rate freezer that does not require expendable liquid nitrogen and the associated pumping, re-filling, and storage challenges posed by a cryogenic liquid. The BioCool simply plugs into a standard electrical outlet and quietly provides low temperature cooling to -40º C. The magnetic stirrer and vortex breaker of the BioCool V40 ensure isothermal conditions throughout its temperature range.
The new generation BioCool V40 benefits from a new controller that provides accurate temperature control with up to 10 point calibration. An intuitive user interface allows for easy navigation and parameter adjustment. The powerful controller enables programming and storage of numerous protocols, each with up to ten distinct segments specifying ramp rate, hold temperature, and hold time. Configuration files can now be programmed, saved, and shared remotely through RS485 communication and a free software package. Unlike liquid nitrogen systems which surround samples with a cold vapour phase, the BioCool V40 immerses samples into a well-circulated, cold liquid bath. The circulating liquid allows more efficient heat transfer to the samples and maintains a more consistent temperature profile at all locations. The source / credit of story is: SP Scientific Inc.
New Biotage® VacMaster™ Disk Vacuum Extraction with Rugged Versatility Biotage AB (Biotage), is pleased to announce the launch of the Biotage®VacMaster™ Disk, a vacuum extraction unit for performing manual, disk-based extractions of semi-volatile organic compounds and hexane-extractable materials (HEMs) from aqueous matrices. Biotage® VacMaster™ Disk extraction unit is a single port vacuum manifold that applies vacuum to the outlet of a solid phase extraction disk to assist in the extraction of aqueous or viscous samples. The easy-to-use unit accommodates both 47 mm and 90 mm disks, as well as a variety of pre-filters to meet the challenges of any sample matrix, regardless of the particulate level. Biotage® VacMaster™ Disk is fully compatible with our recently launched Atlantic® ReadyDisks, as well as our classic Atlantic® Disks, and with all disk holders that utilize luer fittings.
Microbioz India, July 2019
34
Product Launch Designed for high productivity laboratories, the unit is an excellent first step for those customers interested in moving from liquid-liquid extractions to solid phase extractions for sample preparation for environmental, food and beverage, and agriculture applications. Up to eight units can be
linked to the same vacuum source to increase sample throughput; and can be operated within a laboratory fume hood or on a bench top with the vacuum pump’s exhaust port connected to a ventilation system. Each Biotage® VacMaster™ Disk is manufactured in an ISO certified environment (ISO 9001:2015) and constructed from solvent-resistant materials to improve durability in harsh environments. “Biotage® VacMaster™ Disk is a versatile and flexible system for vacuum extraction in a busy laboratory requiring a reliable and rugged workhorse,” says Dan Menasco, Global Technical Product Manager, Analytical, Biotage. The source / credit of story is: Biotage AB
European HITACHIWorkshop at Fraunhofer IMWS The Fraunhofer Institute for Microstructure of
Materials and Systems IMWS expands its range of microstructure diagnostics with Hitachi's HF5000 field emission transmission electron microscope. The presentation of the new microscope took place during a workshop in Halle (Saale). In this meeting, international experts were presented with novel microscopy technologies as well as a demonstration of possible applications of the HF5000. The workshop focused on new research possibilities that arise with the HITACHI HF5000 for nano and surface analysis. By means of an electron beam obtained from a cold field emission source and an electron-optical probe corrector, subangstrom beam diameters can be generated. This provides researchers with even more precise insights into the nanostructure of, for example, glasses, glass-ceramics and optical layers. As a result, microstructural defects can be more clearly recognized, element distributions can be mapped more easily, and work on improving material properties will be significantly accelerated. Global researchers and Hitachi experts spoke at the workshop about working with this cutting-edge microscopy technology. At Fraunhofer IMWS, the first HITACHI HF5000 in Europe was installed. Yasukuni Koga from Hitachi High-Technologies confirmed at the end of the workshop: "We are very pleased to have found a premium partner in Europe with the Fraunhofer IMWS, who fully utilizes the application possibilities of the HF5000. The workshop has confirmed that we can shape the future and expand technological boundaries through this great collaboration." The microscope in Halle is mainly used by the recently founded business unit »Optical Materials and Technologies« of the Fraunhofer IMWS. Prof. Thomas.
Microbioz India, July 2019
36
Product Launch Höche, Head of this business unit, is particularly pleased by this unique selling point. During his presentation he spoke about the added value of the new microscope for the institute and its customers. »I am proud that our team is the first in Europe to work with the HITACHI HF5000. We benefit from the outstanding quality of the element distribution mappings in particular as an applied research institution and thus the companies that we support in the improvement of their products. For example, we can identify microstructural vulnerabilities in materials used in the optical industry or the paint industry more quickly and offer solutions for avoiding them. Our business unit will not only characterize materials down to the atomic level, but also develop them." After the talk, attendees were given a tour to get to know the microscope, how it works, and the lab built specifically for the equipment.
sciences and nanomedical field. Using proprietary Nanoparticle Tracking Analysis (NTA) technology, ZetaView instruments are able to capture the Brownian motion of each particle in a video.
The special feature of the high-resolution, analytical 200-keV scanning transmission electron microscope HF 5000, which combines the TEM and the STEM technology, is the significant increase in performance when acquiring STEM images. Due to the beam generation by means of cold field emission and the implemented probe corrector, the HF5000 can also be used for investigations with only 60 kV acceleration voltage. A special added value is provided by the detectors for excited X-ray radiation, which measure a spatial angle of 2.2 Steradians, which is three times the best TEM / STEM at Fraunhofer IMWS offer so far and contributes to the faster acquisition of elemental distribution images. The source / credit of story is: Hitachi HighTechnologies
Based on the different diffusion movements of large and small particles in the surrounding liquid, ZetaView instruments are able to determine the hydrodynamic diameter of the particles. Furthermore, following the movement of the particles in an applied electric field, the charge state of the particle surface (zeta potential) can be measured. As a consequence, pattern parameters, such as intensity fluctuations, surface geometry and shape of the particles as well as particle concentration are recorded and can be used to distinguish sub-populations. The new ZetaView QUATT has been designed to enhance sample measurement specificity. Through the addition of three additional laser sources, the new instrument expands on the ZetaView's existing fluorescence capability, adding multi-wavelength excitation to its market-leading anti-bleach fluorescence technology. As the names suggest, the ZetaView TWIN houses two excitation lasers and the ZetaView QUATT takes this to the next level, housing four different wavelength lasers. Both instruments have automatic filter sliders which are activated by a simple mouse click in the software to switch between lasers and between fluorescence and scattering modes. With the new exciting ZetaView NTA instrument one, two, or four different fluorophores or dyes with different excitation and emission spectra can be analysed on the same sample, allowing calculation of biomarker ratios. The innovation of multi-wavelength fluorescence-NTA also reduces total measurement times, minimises the amount of sample required and improves experimental reproducibility.
Multi-Wavelength Instrument Improves Nanoparticle Analysis Specificity Analytik has launched the next generation ZetaView® QUATT, with a multi-wavelength video tracking microscope for rapid analysis of size, concentration, fluorescence, electrophoretic mobility and sub-populations of individual nanoparticles. Biological nanoparticles including extracellular vesicles, exosomes, viruses, or virus-like particles are a rapidly growing area of research in the life
Microbioz India, July 2019
38
Product Launch The source / Credit of story is: Analytik Ltd
Metrohm Autolab Partners with Arbin Instruments to Create an Integrated Solution for Battery Research Metrohm Autolab and Arbin Instruments have combined their decades of experience to launch a new Electrochemical Impedance Spectroscopy (EIS) solution that can easily be integrated into any battery testing program. Incorporating EIS into battery research and cell testing provides better insight into battery performance and degradation mechanisms, which improves the accuracy and reliability of the analysis. EIS goes beyond direct signal measurements to provide advanced characterization information, helping to develop safer, faster-charging and longerlasting energy storage systems. "This EIS solution enables battery testing and
research laboratories to gain in-depth understanding of battery performance, especially for automotive, consumer, and industrial applications," said Andre Mijiritskii, CEO of Metrohm Autolab and head of the Metrohm Electrochemistry business at the Metrohm Group. "The Metrohm Group and Arbin Instruments have seen years of fruitful collaboration serving our customers in the growing Energy Storage sector. This joint market launch of the Autolab-Arbin solution is a further step in our ongoing partnership." Antony Parulian, Vice President Marketing & Sales, Arbin Instruments added: â&#x20AC;&#x153;Arbin Instruments is a leading high precision testing equipment manufacturer. Our products are capable of performing columbic efficiency measurements with multi-zone temperature chambers. This partnership offers integrated and easy to use testing solutions
that enable new discovery and characterization metrics for those who play a vital role in energy storage researchâ&#x20AC;?. The Autolab-Arbin solution operates on a single software platform, removing the need to change experiment configurations or download additional
software for data analysis. This new product automates EIS measurements across 1-32 channels with a frequency range of 10 ÎźHz to 1 MHz. The source / credit of story is: Metrohm AG
EAF2000 Advances Complex Charged Molecule Studies Postnova Analytics reports on growing use of its pioneering EAF2000 system to separate and characterize complex proteins, antibodies and viruses as well as charged nanoparticles, colloids and polymers. Launched in 2018, the EAF2000 is the only fieldproven system that combines the principle of
Electrical and Asymmetrical Field Flow Fractionation in a single platform. In an EAF2000 system - Electrical and Cross Flow Fields are applied simultaneously across the FFF channel enabling separation by size and simultaneous measurement of particle charge based on electrophoretic mobility. Combining these two powerful separation techniques in a single platform opens the door to characterizing complex samples that have proven impossible using other techniques. Soheyl Tadjiki, Managing Director of Postnova Analytics Inc., commented "Traditional Flow FFF separations are proven to provide particle size or molar mass distribution data. Using our EAF2000 system allows identifying charge heterogeneities which might be present inside the different size and molar mass fractions. As particle or molecule charge plays a large role in many applications, including protein aggregation, polymer flocculation, and
Microbioz India, July 2019
39
Product Launch particle agglomeration, the EAF2000 opens completely new ways for a significantly better understanding of these phenomena and will quickly help to establish more efficient product development and QC processes". The source / credit of story is: Postnova Analytics GmbH
DuPont Nutrition & Biosciences Introduces HOWARU® PROTECT PRENATAL+ Delivering Clinically Documented Immune, Mood and Vaginal Benefits for Women During Pregnancy. WILMINGTON, Del., June 20, 2019 – DuPont Nutrition & Biosciences has announced the launch of HOWARU® Protect Prenatal+, an innovative probiotic formula that has been clinically proven to deliver mood, vaginal and immune health benefits for women during pregnancy and beyond. DuPont Nutrition & Biosciences is a world leader in microbial biotechnology, health, and nutrition with the broadest range of clinically documented probiotics available in the marketplace. They offer a full range of innovative science-based solutions for improved health and wellness under the brand name HOWARU®, which now features the new HOWARU® Protect Prenatal+. State-of-the-art clinical studies with probiotic supplementation in pregnant women have provided new insights into the health of both mothers and their infants. Among the significant trials has been the ‘Probiotics in Pregnancy Study’ whose primary aim was to assess whether probiotic supplementation in women with Lactobacillus rhamnosus HN001™ provided immune benefits for infants. The secondary aims focused on the health of the mothers and the effect HN001™ supplementation had on the risk of gestational diabetes mellitus (GDM) and postnatal depression. In this “gold-standard” clinical trial of over 400 pregnant women, daily consumption of L. rhamnosus HN001™ by the mother was found to have been associated with a lower prevalence of GDM as well as lower incidence of postnatal depression and anxiety.
Additional clinical trials showed that daily consumption of L. rhamnosus HN001™ by the mother and her infant also helped infants develop a balanced immune system function in the first two years and continued to impact immune health through 11 years. The prevalence of eczema of the children through age 11, the latest time of evaluation, was significantly reduced in the probiotic groups compared to the placebo group. In addition, at ages 6 and 11, there were significant reductions in allergic sensitization scores. The results also showed mothers who had received the HN001™ supplement had improved levels of immune markers in cord blood and breast milk than those in the placebo group, demonstrating immune support for expectant mothers as well. Prescott et al., 2008 Clin Exp Allergy; 39(5):771. HOWARU® Protect Prenatal+, formulated with L. acidophilus La-14® in combination with L. rhamnosus HN001™, has also been proven to support healthy vaginal microbiota and also have beneficial effects regarding recurrent bacterial vaginosis and vulvovaginal candidiasis – two of the most common vaginal complaints among women. This demonstrates that this premium probiotic formulation helps provide full-body wellness for expectant mothers and their unborn children. “At DuPont, we’re focused on improving people’s lives and we’re especially excited to introduce a product that has clinical benefits for such a critical time in life – during pregnancy,” said Anders Gron, DuPont Vice President & Global Business Director- Probiotics, HMOs, & Fibers. DuPont will be showcasing this revolutionary product this year at the IPA World Congress + Probiota Americas – the leading annual event for the prebiotic, probiotic and microbiota focused food and pharma industries in Vancouver, Canada. To learn more about the research backing this formulation and how you can make it an addition to your product portfolio, please stop by our booth to discuss with our leading probiotic experts. To learn more about our probiotic offerings, visit dietarysupplements.dupont.com or howaru.co m.
Microbioz India, July 2019
40
Product Launch
Photostabillity Chamber by Mackpharmatech Pvt Ltd
Mack Pharmatech offers cost effective PLC based Photo stability chambers with European standard “CE” in different capacities. Photo Stability Chambers have Temp. range is 20°C to 50°C, Accuracy : ±0.2°C Uniformity : ±1.0°C &,Control System : PLC (Allen Bradly) . Mack Pharmatech is the only company who gives all equipment with PLC Based Control System, 21 CFR Software, Test samples on Fluorescent light or UV lights separately as well as simultaneously, Lights automatically shut off after a specified exposure level or time duration, HMI (Touch Screen Display), GSM Technology, Hooter System, Full View Glass Door, Bullet feet leveling legs, GMP Model For more information:
Mack Pharmatech Pvt ltd Corporate / Factory Office: B-48, Malegaon MIDC, Sinnar, Dist.-Nasik, Maharashtra 422 113, INDIA Mobile: +91 93259 65656 Telefax: +91-02551-230877 URL: www.mackpharmatech.com E-Mail: sales@mackpharmatech.com
Product Launch
New e-books from Freeman Technology offer updated xpert advice on powder tester selection Recent revisions of two popular e-books from Freeman Technology offer clear, expert advice for those looking to invest in powder testing technology. ‘Choosing a Powder Tester’ reviews the technology available and has been updated to include recent innovations such as uniaxial powder testing.‘The Value of Powder Testing’ considers how test data deliver an economic return and now extends to assessment of the benefits of real-time measurement. Complemented by ‘An Introduction to Powders’, a primer on powder behaviour, both e-books are full of useful information for anyone looking for guidance in this industrially important area.All three e-books are freely available for download at: http://www.freemantech.co.uk/_ebook/
Powder testing techniques range from the simple to the sophisticated with the cost of a tester running up to tens of thousands of pounds. Understanding the strengths and limitations of different techniques and testers is therefore essential when it comes to choosing one that costeffectively meets requirements.
Powder testers vary significantly in terms of their ability to deliver data that is relevant and sufficiently sensitive to solve the problems regularly encountered when dealing with powders, whether in R&D or manufacturing.
‘Choosing a PowderTester’ covers the majority of testing techniques in routine use including all USP methodsThe latest edition includes avalanche methods and uniaxial testing, a technique advanced by Freeman Technology that ranks powder flowability in an analogous way to shear cell testing but using asimpler more direct method. The e-book includes a brief description of the principles underpinning each technique along with a discussion of strengths and limitations,providing the information needed to make a choice that is well-matched to individual requirements. The results of powder testing can include faster progress in R&D, secure identification of a cheaper raw material, effective troubleshooting of a process problem and/or higher product quality. All such gains are associated with tangible economic benefits. The Value of Powder Testing explains howto estimate the payback on testing, with the latest edition including an example study based on the utilisation of in-line powder flow monitoring, as exemplified by the Lenterra Flow Sensor System, for which Freeman Technology is the exclusive worldwide distributor. Find out more about Freeman Technology products including the Uniaxial Powder Tester and the Lenterra Flow Sensor System at: http://www.freemantech.co.uk/_powders/powde r-testing-instrumentation To download the e-books go to: http://www.freemantech.co.uk/_ebook/ For more information: rajiv@apexchromatography.com
Microbioz India, July 2019
41
Product Launch
Telstar launches BiOptima, a new high-end biosafety cabinet A new ergonomic human-centred cabinet, totally adapted to the operatorâ&#x20AC;&#x2122;s physical features and requirements Terrassa (Barcelona) 2019, July 1st.Telstar has launched an innovative range of high-end Class II Biological Safety Cabinets providing higher performance, comfort, cleanability and energy savings. Designed to be completely adapted to the operatorâ&#x20AC;&#x2122;s physical attributes, the new ergonomic BiOptima cabinet is intended to be used for high-risk microbiological research and highly toxic applications featuring low noise levels, low power consumption and low maintenance costs.
Developed by Telstar, the new high-end Class II biosafety cabinet ensures optimum efficiency and high-level energy savings, as well as presenting a new breakthrough ergonomic design. BiOptima series is available in two versions: a BiOptima standard model integrated with two HEPA filters, according to the EN12469 standard, for microbiological research with biological agents (bacteria, viruses, etc.) and allergens and BiOptimaCyto, including three HEPA filters, according to the DIN12980 norm, addressed to work with high-risk microbiological and highly toxic applications, such as the production of cytotoxic drugs.
BiOptima standard version provides operator protection with the inflow air barrier, product protection thanks to HEPA-filtered laminar downflow in the working area and environmental protection through the exhaust HEPA filter. BiOptimaCyto is equipped with additional Vshaped HEPA filters underneath the work surface, which filter the inflow air and keep the internal construction of the cabinet free of contamination, ensuring greater safety for high risk applications.
The new cabinet offers a very spacious work area, 550 mm in depth and 700 mm in height, which enables productivity and comfort with plenty of space, in a smart compact design with an overall height of only 1450 mm. Easy to clean, the working chamber in one piece is made in AISI 304 Stainless Steel with rounded edges inside the cabinet to facilitate effective disinfection and maximize contamination prevention. In addition, the electrically operated front window slides upwards offering 500 mm height access. Characteristic features of BiOptima Series are the ergonomic sloped front window, easy-to-clean hinged front window, V shaped front grills and rounded arm rest for maximum comfort, energy efficient dimmable Led light, energy saving EC fans, standard fitted UV light, worktop with air slots, a maintenance reducing full size pre-filter, liquid collecting drip tray underneath the work surface, electrically operated front window with back-up battery, and patented 4F System (Fast, Friendly and eFFicient) to facilitate replacement of the filters.BiOptima is equipped with a full size G3 pre-filter under the work surface that prevents large particles or dust from reaching the HEPA filters, effectively doubling HEPA filter lifetime. BIOPTIMA, developed in accordance with the European EN 12469 standard for Microbiological Safety Cabinets, has been certified by TUV Nord in Hamburg (Germany).
For more information: Telstar Phone: +34 93 736 16 00 Website:www.telstar.com E-mail: pr@telstar.com
Microbioz India, July 2019
42
Guest Post
Take a look at Blood with analysis machines High-tech machines analyze human blood samples, detect coagulation disorders and thus help to save lives. The maxon sales company in France does not only supply the appropriate drives – in fact, it builds entire conveyor modules. A peek inside. mdp technician Yannik Charel assembles the transport unit for the medical Our blood is a fascinating analysis device. ©maxon motor fluid it transports oxygen and nutrients, fends off foreign objects and closes Fully automated blood analysis wounds. At least in normal cases some people, however, suffer from coagulation disorders. These Stago is a French company that specializes in cases are unpleasant for the patient and can have analysis instruments for hemostasis diagnostics, in severe consequences – or even lead to death. This other words for testing blood clotting. Around is why early detection of a blood disorder and the 20,000 devices of Stago are in use across the world – including the StarMax. hunt for a cure are so important. This requires a lot of testing. Analysis devices in laboratories and This fully automated analysis system is equipped hospitals run around the clock and are able to with a three-axes robot and offers space for 215 autonomously pipette samples to deliver quick samples and 1,000 test containers. The machine results. Such industrial automation equipment has works autonomously, checks the results, compares to work with high accuracy and reliability. This them and monitors the processes. This saves the places high demands on all components and the biologists and technicians a lot of time. Therefore, developers. the device is particularly suitable for laboratories with a large sample volume.
The analysis system STAR Max. Image ©Stago
«mdp and maxon contributed their specialized know-how and gave us valuable tips. » Jean-François Gelin, Project manager at Stago Microbioz India, July 2019 44
Guest Post Precision on three axes StarMax was introduced to the market in late 2014. Yet Stago developed its first analysis device with an X-Y-Z-axis robot as early as 1991. Even back then, mdp, maxon motor’s sales company in France, was on board. Therefore, the drive specialist was contacted again during the first development phase of StarMax, to clarify the most important questions: How can precise movement be achieved on all three axes? How can the reagents be pipetted fully automatically? “In the end, mdp used their vast experience to adapt their standard products to match our requirements,” says Jean-Francois Gelin, Project Manager Innovation and R&D at Stago. “Additionally mdp and maxon contributed their specialized knowhow and gave us valuable tips.”
Easy motor control The cooperation has now become so close that mdp assembles the complete conveyor system for the pipette racks in its own production facilities in Neyron and ships it to Stago for final assembly.
maxon A-max 22 DC motor This brushed drive with 6 W of power offers excellent value for money.
Various types of the A-max DC motor by maxon are used for the movements of the rack. The diameters vary between 16 and 26 millimeter. The DC motors are highly dynamic and easy to control. Additionally mdp installs matching planetary gear heads to generate the required torques. The maxon sales company therefore is not only a drive specialist, but also an expert in the fields of mechatronics and automation. “Our company slogan – Motors, Systems, Solutions – reflects that,” says Alain Pontille, Managing Director at mdp. “We work very closely with our customers and jointly create solutions that make their products an economic success.” This worked very well for Stago. “When we started developing hemostasis analysis machines, hardly anybody believed in our success,” says JeanFrançois Gelin of Stago. Today the company has more than 2,100 employees and delivers its highend products to more than 110 countries.
maxon GP 22 gearhead This planetary gearhead with a diameter of 22 mm provides the necessary torque for the application.
For additional information, please contact: maxon precision motor India Pvt Ltd
Niran Arcade, No.563/564, 2nd Floor, New BEL Road, RMV II stage, Bangalore- 560 094 Phone: 91 80 41734132 E-mail: info.in@maxonmotor.com Web site: www.maxonmotor.in
Microbioz India, July 2019
45
Product Launch
Radio-opaque silicone tube by Amipolymer Pvt ltd Now a day silicone based biocompatible Polymers are used to produce catheters and other devices that are inserted into the body for interventional procedures. Part inserted are commonly filled with substances opaque to x-rays, thereby rendering the devices visible under fluoroscopy or x-ray imaging. These fillers, or radiopacifiers are based on typically dense metal or metallic salt powders affect the energy attenuation of photons in an xray beam as it passes through matter, reducing the intensity of the photons by absorbing or defecting them. Because these materials exhibit a higher attenuation coefficient than soft tissue or bone, they appear lighter on a fluoroscope or x-ray film. This visibility provides idea about accurately position the device in the affected area. Image contrast and sharpness can be varied by the type and amount of radio pacifier used.
Figure 3 X-Ray Radiology
Device design is also a factor like a higher loading of radiopaque material, for instance, is needed for thin-wall catheter tubing than for products with thicker walls. Generally, compounds should contain only the amount of additives absolutely required for the application, since overloading can result in the loss of the polymer's mechanical properties. Blending together several radiopaque materials can produce better results than using only one type in a formulation.
Figure 1 Characteristics X-Ray generation
Among the most widely used radio pacifiers for medical devices are barium sulfate, bismuth compounds, and tungsten metals that are excellent absorbers of x-rays. Selection of the correct fillers in the proper amount requires a thorough understanding of attenuation and how it is affected by various radiopaque compounds.
Figure 2 Radiopaque catheter for interventional procedure
X-rays are belonging from electromagnetic radiations family having a range of wavelengths. Diagnostic x-rays fall near the shorter-wavelength end of the spectrum, measuring between 1 Ă&#x2026; and 0.1 Ă&#x2026;. X-rays are produced from the conversion of energy that results when fast-moving electrons from the element of an x-ray tube interact with a tungsten anode or target. The kinetic energy of the electrons increases as voltage (Kvp). The intensity of an x-ray beam is determined by the number of photons in the beam and the energy of the photons in terms of Kev. Microbioz India, July 2019
47
Product Launch Material: Barium Sulfate. Barium sulfate (BaSO4) was the first radiopaque material to be widely compounded in medical formulations and is the most common filler used with medical-grade polymers. It is a non-harmful filler having specific gravity of 4.5. For optimize X-ray imaging during interventional procedure normal doses are 20 to 40 PHR. Higher doses might be destroy base polymer physical properties. Bismuth. Considerably more expensive than barium. Bismuth trioxide (Bi2O3), which is yellow in color, has a specific gravity of 8.9. Since
bismuth produces a brighter, sharper, highercontrast image on an x-ray film than does barium, it is commonly used where a high level of radiopacity is required. Tungsten. It is a fine metal powder with a specific gravity of 19.35. Tungsten (W) is more
than twice as dense as bismuth and can provide a high attenuation coefficient. Higher level of loading is possible up to 60% for better attenuation and image contrast but beyond that surface roughness is taken place. Medical devices used in diagnostic radiology must be easily seen on x-ray film and fluoroscopes in order for medical practitioners to precisely position them inside the body during critical procedures. The type and amount of radiopaque filler Compounded with silicone elastomer in the manufacture of these devices determines how they appear.
By: Pritam Adhikary (Executive-R&D) Ami Polymer Pvt. Ltd. # +91 82389 22236
research@amipolymer.com
PUBLISHED ON: 15th July 2019 RNI NUMBER: UPENG/2017/73675